Gain Therapeutics (NASDAQ:GANX) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Gain Therapeutics (NASDAQ:GANX) in a report published on Monday,Benzinga reports. The firm currently has a $8.00 price target on the stock.

Several other brokerages also recently commented on GANX. Scotiabank began coverage on shares of Gain Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $12.00 price objective on the stock. Chardan Capital reaffirmed a “buy” rating and set a $6.00 price target on shares of Gain Therapeutics in a report on Friday, March 28th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $8.20.

Gain Therapeutics Stock Down 2.5%

Shares of NASDAQ GANX opened at $1.96 on Monday. The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.04. Gain Therapeutics has a 12 month low of $0.89 and a 12 month high of $3.19. The firm has a market capitalization of $57.93 million, a PE ratio of -1.78 and a beta of 0.17. The firm has a fifty day simple moving average of $1.94 and a two-hundred day simple moving average of $2.01.

Gain Therapeutics (NASDAQ:GANX) last released its earnings results on Wednesday, May 14th. The company reported ($0.16) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.16). Equities analysts expect that Gain Therapeutics will post -1 earnings per share for the current year.

Hedge Funds Weigh In On Gain Therapeutics

Institutional investors have recently made changes to their positions in the business. Sprott Inc. bought a new position in shares of Gain Therapeutics in the 4th quarter worth approximately $30,000. Benedict Financial Advisors Inc. bought a new stake in Gain Therapeutics during the 4th quarter worth approximately $35,000. Bridgeway Capital Management LLC bought a new stake in Gain Therapeutics during the 4th quarter worth approximately $65,000. Kovitz Investment Group Partners LLC bought a new stake in Gain Therapeutics during the 1st quarter worth approximately $91,000. Finally, Northern Trust Corp raised its stake in Gain Therapeutics by 88.2% during the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock worth $183,000 after acquiring an additional 39,642 shares during the period. Institutional investors own 11.97% of the company’s stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.